Venus Medtech (Hangzhou), Inc. Class H

Venus Medtech (Hangzhou), Inc. Class H

0.13
USD
-0.29
(-68.64%)
Apr 01Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.05
0.29
0.75
0.67
0.95
0.93
1.12
1.08
0.7
- -
Basic EPS, GAAP
-0.4
-0.77
-1.22
-0.44
-0.85
-2.42
-1.61
-1.63
-0.93
- -
Free Cash Flow per Basic Share
-0.26
-0.45
-1.05
-0.88
-1.37
-2.07
-1.99
-0.04
-0.76
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.18
1.18
7.51
9.02
10.31
8.18
6.62
5.01
4
3.48
Tangible Book Value per Share
0.12
-0.51
5.85
7.28
8.43
3.98
3.05
1.65
0.79
0.4
Basic Weighted Avg Shares
393
393
311
409
439
438
438
438
438
438
Sales/Revenue/Turnover
18
115
233
276
416
406
491
471
307
- -
Operating Margin (%)
-847.18
-255.3
-136.69
-53.92
-65.4
-156.2
-116.22
-73.61
-106.72
- -
Depreciation Expense
6
10
29
38
52
112
125
111
97
- -
Net Income, GAAP
-157
-300
-381
-182
-374
-1,058
-704
-714
-408
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-861.77
-260.45
-163.21
-65.93
-89.85
-260.22
-143.22
-151.71
-132.89
- -
Working Capital
26
-205
2,336
2,955
3,231
1,977
803
441
426
108
LT Debt
4
15
17
22
48
654
331
313
21
7
Total Equity
81
470
3,046
3,857
4,632
3,631
2,919
2,211
1,763
1,526
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-112.55
-21.76
-5.31
-8.94
-25.94
-21.56
-27.84
-20.52
- -

Capital Structure

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
202
41
195
LT Borrowings
258
- -
- -
LT Finance Leases
33
21
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
441
441
438
Market Capitalization
808
833
- -

Working Capital

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
733
667
462
Cash, Cash Equivalents & STI
293
264
71
Accounts Receivable, Net
138
99
93
Inventories
104
97
93
Total Current Liabilities
403
241
355
Payables & Accruals
- -
- -
- -
ST Debt
202
41
195
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-13.13%
-20.28%
Free Cash Flow
- -
355.96%
1,764.03%
Net Income, GAAP
- -
42.7%
-42.92%
Sales/Revenue/Turnover
- -
6.05%
-34.84%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
471
2025
- -
- -
307
2026
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-1.63
2025
- -
- -
-0.93
2026
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

CEO
Hou-Sen Lim
Full Time Employees
560
Sector
Health technology
Industry
Medical specialties
Address
No. 88, Jiangling Road Wanchai WA China 310051
IPO Date
Dec 10, 2019
Business
Venus Medtech (Hangzhou) Inc. specializes in the research, development, and commercialization of advanced transcatheter heart valve medical solutions, serving patients across Mainland China and internationally. The company offers a diverse portfolio, including its VenusA-Valve system for treating severe aortic stenosis, along with the enhanced VenusA-Plus and VenusA-Pro transcatheter aortic valve replacement (TAVR) devices. For pulmonary valve dysfunction, the VenusP-Valve stands out as a pioneering self-expanding transcatheter pulmonary valve replacement (TPVR) system, which has achieved approvals in both China and Europe and is currently undergoing a pivotal clinical study in the United States. Beyond its established products, the company is actively developing next-generation dry-valve TAVR candidates like Venus-Vitae and Venus-PowerX, alongside innovative transcatheter systems such as Cardiovalve for both mitral and tricuspid valve replacement therapies. Venus Medtech also provides the Liwen RF ablation system for hypertrophic cardiomyopathy and is advancing renal denervation devices for hypertension management. Complementary products include the V8/TAV8 balloon aortic valvuloplasty catheters and the TriGUARD3 cerebral embolic protection device, designed to safeguard against brain damage during TAVR and other intricate structural heart procedures. Established in 2009, Venus Medtech is headquartered in Hangzhou, People's Republic of China, and continues to expand its global footprint and clinical innovations.